Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1998-8-13
|
pubmed:abstractText |
The aim of this study was to compare the efficacy of 100 micrograms of salbutamol inhaled from a new metered-dose powder inhaler (MDPI, Leiras Taifun, Finland) with that of a same dose of salbutamol inhaled from a conventional pressurized metered-dose inhaler with a large volume spacer (pMDI + S) in protecting against methacholine (Mch) induced bronchoconstriction. This was a 3 day, randomized, cross-over, partly blinded, placebo-controlled multicentre study where the pMDI + S was used as an open control. Twenty-six asthmatic outpatients with a baseline FEV1 > or = 60% of predicted and with bronchial hyperreactivity (PD20 FEV1 < or = 890 micrograms of Mch) were studied. On each study day the patients underwent an Mch provocation 30 min after inhaling placebo from the MDPI or a dose of 100 micrograms of salbutamol from the MDPI and from the pMDI + S. PD20 FEV1 and dose-response slope [DRS; maximal change in FEV1 (%)/dose of Mch (mumol)] were used to evaluate efficacy. The median values of PD20 FEV1 were 250, 622 and 1737 micrograms after placebo MDPI, salbutamol pMDI + S and salbutamol MDPI, respectively. The corresponding DRS values were -11.0%, -4.5% and -2.0% mumol-1. With both parameters, all differences were statistically significant (P < 0.05). In conclusion, 100 micrograms of salbutamol inhaled from Leiras Taifun MDPI offers better protection against Mch-induced bronchoconstriction than 100 micrograms of salbutamol from a pMDI connected to a large volume spacer device.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0954-6111
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
578-83
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9692126-Adult,
pubmed-meshheading:9692126-Albuterol,
pubmed-meshheading:9692126-Bronchial Hyperreactivity,
pubmed-meshheading:9692126-Bronchodilator Agents,
pubmed-meshheading:9692126-Cross-Over Studies,
pubmed-meshheading:9692126-Double-Blind Method,
pubmed-meshheading:9692126-Female,
pubmed-meshheading:9692126-Forced Expiratory Volume,
pubmed-meshheading:9692126-Humans,
pubmed-meshheading:9692126-Male,
pubmed-meshheading:9692126-Middle Aged,
pubmed-meshheading:9692126-Nebulizers and Vaporizers
|
pubmed:year |
1998
|
pubmed:articleTitle |
The bronchoprotective efficacy of salbutamol inhaled from a new metered-dose powder inhaler compared with a conventional pressurized metered-dose inhaler connected to a spacer.
|
pubmed:affiliation |
Leiras Oy, Turku, Finland.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|